
Iovance Biotherapeutics (IOVA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $-0.05 | $-0.09 | 44.4 % |
| Q2 | Aug 6, 2026 | $-0.11 | $-0.14 | 21.4 % |
| Q1 | May 7, 2026 | $-0.19 | $-0.16 | -18.8 % |
| Q4 | Feb 24, 2026 | $-0.18 | $-0.19 | 5.26 % |
Quarterly Revenue (Billions)
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $121.46M | $115.99M | 4.72 % |
| Q2 | Aug 6, 2026 | $99.31M | $87.60M | 13.4 % |
| Q1 | May 7, 2026 | $71.43M | $75.95M | -5.96 % |
| Q4 | Feb 24, 2026 | $86.77M | $78.64M | 10.3 % |
Iovance Biotherapeutics (IOVA) last issued guidance on November 5, 2026 for fiscal year 2026. The company guided revenue in the range of $410M - $420M for the period.
Compared to prior guidance, Iovance Biotherapeutics maintained its revenue forecast from a prior range of $410M - $420M.
Iovance Biotherapeutics has issued 14 guidance updates between August 8, 2024 and November 5, 2026. During this period, the company raised its outlook 4 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.09 | $-0.14 | $-0.16 | $-0.19 |
| Actual | $-0.05 | $-0.11 | $-0.19 | $-0.18 |
| Surprise | +44.4% | +21.4% | -18.8% | +5.26% |
| Revenue | ||||
| Estimate | $116.0M | $87.6M | $76.0M | $78.6M |
| Actual | $121.5M | $99.3M | $71.4M | $86.8M |
| Surprise | +4.72% | +13.4% | -5.96% | +10.3% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.05 | $-0.06 | $-0.09 | $-0.10 |
| Revenue | ||||
| Consensus | $127.7M | $133.1M | — | — |